Associations - PD-L1 underexpression

BIOMARKER:

PD-L1 underexpression

Entrez ID:

29126

Related biomarkers:

‹

›

PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
PD-L1 underexpression PD-L1 underexpression	Lung Adenocarcinoma LUAD	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	nivolumab Resistant: B - Late Trials nivolumab Resistant : B
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	camrelizumab Sensitive: C3 – Early Trials camrelizumab Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	ipilimumab + cemiplimab Sensitive: C3 – Early Trials ipilimumab + cemiplimab Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Urothelial Cancer Urothelial Cancer	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Mantle Cell Lymphoma Mantle Cell Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
PD-L1 underexpression PD-L1 underexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Acute Myelogenous Leukemia AML	XmAb14045 Sensitive: C3 – Early Trials XmAb14045 Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
PD-L1 underexpression PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab sarotalocan Sensitive: C3 – Early Trials cetuximab sarotalocan Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Gastric Adenocarcinoma Gastric Adenocarcinoma	toripalimab + surufatinib Sensitive: C3 – Early Trials toripalimab + surufatinib Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	toripalimab + surufatinib Sensitive: C3 – Early Trials toripalimab + surufatinib Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Colorectal Cancer CRC	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3
PD-L1 underexpression PD-L1 underexpression	Renal Cell Carcinoma RCC	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES